Term Name: lorlatinib
Synonyms: (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, loratinib, Lorbrena, lorlatinib, lorlatinibum, PF-06463922, PF06463922, PFE-PKIS 10
Definition: A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.
Ontology: ChEBI [CHEBI:143117]  ( EBI )

Relationships
is a type of: aminopyridine aromatic ether azamacrocycle benzamides cyclic ether monofluorobenzenes nitrile organic heterotetracyclic compound pyrazoles
has_role: antineoplastic agent EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor